| scholarly article | Q13442814 |
| P2093 | author name string | Giovanni Blandino | |
| Sabrina Strano | |||
| Stefania Dell'Orso | |||
| Olimpia Monti | |||
| Silvia Di Agostino | |||
| Giulia Fontemaggi | |||
| Eleonora Lapi | |||
| Adriana Maria Mongiovi | |||
| P2860 | cites work | The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage | Q22010200 |
| p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage | Q22010201 | ||
| Physical interaction with Yes-associated protein enhances p73 transcriptional activity | Q24291023 | ||
| ASPP1 and ASPP2: common activators of p53 family members | Q24305256 | ||
| Mdm2 promotes the rapid degradation of p53 | Q24322597 | ||
| A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants | Q24530763 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| A common polymorphism acts as an intragenic modifier of mutant p53 behaviour | Q28118809 | ||
| Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis | Q28138604 | ||
| MDM2--master regulator of the p53 tumor suppressor protein | Q28138926 | ||
| Cancer statistics, 2002 | Q28216788 | ||
| Mutations in the p53 gene occur in diverse human tumour types | Q28249770 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis | Q28345092 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| Cancer. p53, guardian of the genome | Q29615610 | ||
| Tumor spectrum analysis in p53-mutant mice | Q29617436 | ||
| T antigen is bound to a host protein in SY40-transformed cells | Q29618321 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Emerging molecular markers of cancer. | Q30330271 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants | Q32129086 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| P63 and P73: P53 mimics, menaces and more | Q34185768 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth | Q34402080 | ||
| Li-Fraumeni syndrome: a p53 family affair | Q34421596 | ||
| Li-Fraumeni syndrome – a molecular and clinical review | Q34432117 | ||
| Assessing TP53 status in human tumours to evaluate clinical outcome | Q34570100 | ||
| TP53 and head and neck neoplasms | Q35078742 | ||
| Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation | Q35089377 | ||
| Regulation of p53 responses by post-translational modifications | Q35116637 | ||
| Decision making by p53: life, death and cancer | Q35116663 | ||
| Hot-spot mutants of p53 core domain evince characteristic local structural changes. | Q35549859 | ||
| Transcriptional activities of mutant p53: when mutations are more than a loss | Q35902152 | ||
| p53 mutation heterogeneity in cancer | Q36113160 | ||
| p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma | Q36115578 | ||
| Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide | Q37088668 | ||
| Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. | Q38291171 | ||
| Transactivation of the EGR1 gene contributes to mutant p53 gain of function | Q38334166 | ||
| Comparison of the effect of mutant and wild-type p53 on global gene expression | Q38334169 | ||
| A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain | Q39458140 | ||
| p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. | Q39610993 | ||
| Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells | Q40237209 | ||
| Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. | Q40439787 | ||
| Modulation of gene expression by tumor-derived p53 mutants | Q40502644 | ||
| ONYX-015 selectivity and the p14ARF pathway | Q40700227 | ||
| Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor | Q41192780 | ||
| Gain of function mutations in p53. | Q41557652 | ||
| p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis | Q44426545 | ||
| Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients | Q45130745 | ||
| Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). | Q45180301 | ||
| A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). | Q47587088 | ||
| Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma | Q47976180 | ||
| Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome | Q52561781 | ||
| p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. | Q53411999 | ||
| Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression | Q53415195 | ||
| A transgenic mouse model for mammary carcinogenesis | Q53436081 | ||
| Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73 | Q57778801 | ||
| p63 and p73 are required for p53-dependent apoptosis in response to DNA damage | Q59065672 | ||
| Estimates of the worldwide frequency of sixteen major cancers in 1980 | Q68257962 | ||
| Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma | Q71466524 | ||
| Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck | Q72541492 | ||
| Chemosensitivity linked to p73 function | Q73342473 | ||
| p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck | Q73358736 | ||
| Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain | Q73400021 | ||
| p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas | Q73504503 | ||
| p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma | Q73690528 | ||
| TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer | Q74531141 | ||
| Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy | Q77932308 | ||
| Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome | Q81166001 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 488-496 | |
| P577 | publication date | 2007-05-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Head & Neck | Q13703062 |
| P1476 | title | Mutant p53 proteins: between loss and gain of function | |
| P478 | volume | 29 |
| Q42730762 | A common carcinogen benzo[a]pyrene causes p53 overexpression in mouse cervix via DNA damage |
| Q53260896 | Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas |
| Q37344081 | Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. |
| Q35653073 | Identification of genomic features in the classification of loss- and gain-of-function mutation. |
| Q48690318 | Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. |
| Q30354662 | Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. |
| Q26749382 | Oncogenic Intra-p53 Family Member Interactions in Human Cancers |
| Q30416701 | PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations |
| Q38286198 | Pharmacological reactivation of p53 as a strategy to treat cancer. |
| Q38956978 | Recognition of Local DNA Structures by p53 Protein. |
| Q34236112 | Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta |
| Q27006998 | Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53 |
| Q24306101 | Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity |
| Q34159403 | Selective Depletion of Mutant p53 by Cancer Chemopreventive Isothiocyanates and Their Structure−Activity Relationships |
| Q35004008 | Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice |
| Q36941044 | Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. |
| Q42397956 | The Expression Levels of XLF and Mutant P53 Are Inversely Correlated in Head and Neck Cancer Cells. |
| Q36191906 | The Expression and Correlation of iNOS and p53 in Oral Squamous Cell Carcinoma |
| Q39794563 | The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. |
| Q47121352 | Tumor suppressor protein p53-mediated repression of human mitotic centromere-associated kinesin gene expression is exerted via down-regulation of Sp1 level. |
| Q38069463 | p53 mutations in cancer |
Search more.